Skip to main content
. 2023 Dec 24;3(2):100177. doi: 10.1016/j.focus.2023.100177

Table 2.

Odds of Implementing Different Types of MOUD Accommodations Over COVID-19 Time Periods, Among MOUD Providers Who Had Not Already Implemented Accommodation Before COVID-19, Arizona 2021

Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 Model 9 Model 10
Accommodation type Telehealth Buprenorphine induction through telehealth Multiday dosing License reciprocity Home delivery
Covariates
 Higher patient limit (100 or 275) (ref category: patient limit=30) 3.5a (2.3) 4.2* (3.0) 5.4** (3.1) 5.4** (3.1) 2.4 (1.4) 2.2 (1.3) 16.2* (17.7) 21.9** (24.4) 1.7 (1.2) 1.6 (1.1)
 Rural provider (ref category: urban provider) 0.25a (0.20) 0.24a (0.20) 1.4 (1.0) 1.2 (0.85) 0.77 (0.63) 0.63 (0.49) 0.35 (0.41) 0.26 (0.31) 1.9 (1.4) 2.1 (1.6)
 Provider offering methadone (ref category: provider does not offer methadone) 0.95 (0.68) 1.6 (0.96) 11*** (7.2) 0.49 (0.36) 0.46 (0.40)
 Stand-alone methadone clinic (ref category: other healthcare facility) 0.61 (0.63) 0.94 (0.73) 32.7** (36.2) 0.20a (0.19) 0.67 (0.80)
 SUD clinic (excluding stand-alone OTPs) (ref category: other healthcare facility) 0.53 (0.47) 1.2 (0.89) 3.4a (2.3) 0.17 (0.20) 1.7 (1.5)
 Constant 1.13 (0.55) 1.23 (0.59) 0.25** (0.13) 0.29* (0.14) 0.22** (0.11) 0.26** (.13) 0.04** (0.04) 0.05** (0.05) 0.22* (0.13) 0.18** (0.11)
Number of observations (number of providers who had not already implemented examined accommodation) 50 50 63 63 72 72 72 72 53 53

Note: Boldfaces indicate statistical significance (*p<0.05, **p<0.01, ***p<0.001).

Two models are presented for each outcome owing to the high collinearity between the medication-type variable and the practice-setting variables. The coefficients presented are in the form of ORs with corresponding SEs below in parentheses.

a

p<0.10.

MOUD, medication for opioid use disorder; OTP, opioid treatment program; SUD, substance use disorder.